Venrock Healthcare Capital Partners III, L.P. bought $1.4M of ORKA
owner at Oruka Therapeutics, Inc.. 122,882 shares at an average of $11.45, traded Feb 10, 2025, filed Feb 27, 2025.
Score components
- +12Role10% owner
- +25Trade size$1.4M at market
- 0Relative to holdingsHoldings up 3.1%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +30.8%, 3m +24.0%, 6m +59.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-005908, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2025 | POpen-market purchase Common Stockindirect: By Funds | +574 | $10.90 | $6,257 | 4,026,120 | Feb 27, 2025 |
| Feb 11, 2025 | POpen-market purchase Common Stockindirect: By Funds | +9,593 | $10.95 | $105k | 4,035,713 | Feb 27, 2025 |
| Feb 12, 2025 | POpen-market purchase Common Stockindirect: By Funds | +8,971 | $11.86 | $106k | 4,044,684 | Feb 27, 2025 |
| Feb 13, 2025 | POpen-market purchase Common Stockindirect: By Funds | +14,950 | $11.63 | $174k | 4,059,634 | Feb 27, 2025 |
| Feb 14, 2025 | POpen-market purchase Common Stockindirect: By Funds | +88,794 | $11.44 | $1.0M | 4,148,428 | Feb 27, 2025 |
Related signals
Other insiders at Oruka Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $806k 9,999 shares | -41% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $2.1M 25,000 shares | -3% | |
| 17Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $51k 533 shares | -4% | |
| 29Weak | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $936k 10,000 shares | -25% | |
| 29Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $926k 10,019 shares | -40% | |
| 21Weak | Oruka Therapeutics, Inc. | Joana Goncalves Chief Medical Officer | $734k 7,947 shares | -20% | |
| 53Moderate | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $235k 2,452 shares | -0% | |
| 44Moderate | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $87k 906 shares | -0% | |
| 40Moderate | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $99k 1,039 shares | -3% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $6.9M 75,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.